Hansa Biopharma AB (publ) (STO:HNSA)
45.14
-2.18 (-4.61%)
Nov 20, 2026, 5:29 PM CET
Hansa Biopharma AB Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Hansa Biopharma AB stock has a consensus rating of "Strong Buy" and an average price target of krĀ 72.00. The average 1-year stock price forecast is 59.50% higher than the current stock price, while the lowest is krĀ 36.00 (-20.25%) and the highest is krĀ 103.00 (+128.18%).
Price Target: krĀ 72.00 (+59.50%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Hansa Biopharma AB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains krĀ 103.00 | Buy | Maintains | krĀ 103.00 | +128.18% | Nov 13, 2026 |
Financial Forecast
Revenue This Year
1.19B
from 222.27M
Increased by 435.40%
Revenue Next Year
411.53M
from 1.19B
Decreased by -65.42%
EPS This Year
1.33
from -5.79
EPS Next Year
-5.07
from 1.33
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.